ACT-IOP-003-CLN-002: A First-in-Human, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003) Once Weekly or Twice Weekly Following First-Line Systemic Chemotherapy in Participants with Nonresectable Pancreatic Cancer

A First-in-Human, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003) Once Weekly or Twice Weekly Following First-Line Systemic Chemotherapy in Participants with Nonresectable Pancreatic Cancer
Principal Investigator
Boone, Brian
Phase
I (Cancer Control)
Age Group
Adult
Applicable Disease Sites
Gastrointestinal Cancers
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Nina Moore, RN
Research Specialist
Phone: +1 304-293-2991
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.